Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept plus recombinant human erythropoietin in low-risk MDS with anemia
ChiCTR2300070683Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of luspatercept and erythropoietin in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Hemoglobin response rate during 12-week treatment period. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
luspatercepterythropoietin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2300070683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070683.